Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Символ: 300357.SZ
SHZ
25.97
CNYПазарна цена днес
39.7338
Съотношение P/E
12.9135
Коефициент PEG
13.60B
MRK Cap
- 0.01%
Доходност на DIV
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357-SZ) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5029.87 | 1288.8 | 1135.7 | 1020.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 413.5 | 117.4 | 295.1 | 370.9 | |||||||||||||||
balance-sheet.row.net-receivables | 1009.12 | 214.9 | 284.9 | 256.2 | |||||||||||||||
balance-sheet.row.inventory | 227.66 | 59 | 48.4 | 53.8 | |||||||||||||||
balance-sheet.row.other-current-assets | 52.77 | 7.2 | 8.1 | 10.7 | |||||||||||||||
balance-sheet.row.total-current-assets | 6319.42 | 1569.9 | 1477.1 | 1341.5 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 2676.62 | 704.8 | 444.6 | 301.6 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 751.98 | 188.4 | 189.5 | 176.4 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 751.98 | 188.4 | 189.5 | 176.4 | |||||||||||||||
balance-sheet.row.long-term-investments | -21.32 | -43.2 | -216.7 | -287.6 | |||||||||||||||
balance-sheet.row.tax-assets | 21.79 | 5 | 4.9 | 5.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 389.15 | 137.2 | 298.4 | 394.3 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 3818.23 | 992.3 | 720.7 | 590.5 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 10137.65 | 2562.2 | 2197.9 | 1932 | |||||||||||||||
balance-sheet.row.account-payables | 29.67 | 8 | 7.7 | 5.1 | |||||||||||||||
balance-sheet.row.short-term-debt | 151.91 | 41.2 | 4 | 5.9 | |||||||||||||||
balance-sheet.row.tax-payables | 82.02 | 14.5 | 30.3 | 62.9 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 68.36 | 21.3 | 12.3 | 1.9 | |||||||||||||||
Deferred Revenue Non Current | 124.32 | 30.9 | 27.4 | 24.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0.81 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 541.25 | 127.5 | 91.1 | 96.6 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 308 | 81.4 | 68 | 27.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 68.36 | 21.3 | 12.3 | 1.9 | |||||||||||||||
balance-sheet.row.total-liab | 1033.27 | 258.5 | 170.8 | 135.4 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 2094.34 | 523.6 | 523.6 | 523.6 | |||||||||||||||
balance-sheet.row.retained-earnings | 4996.92 | 1262.6 | 1092.7 | 889.6 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1273.53 | 270.7 | 235.1 | 194.7 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 256.39 | 128.2 | 128.2 | 128.2 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 8621.17 | 2185.1 | 1979.6 | 1736.1 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 10137.65 | 2562.2 | 2197.9 | 1932 | |||||||||||||||
balance-sheet.row.minority-interest | 483.2 | 118.6 | 47.5 | 60.5 | |||||||||||||||
balance-sheet.row.total-equity | 9104.38 | 2303.7 | 2027.1 | 1796.6 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 10137.65 | - | - | - | |||||||||||||||
Total Investments | 392.18 | 74.2 | 78.4 | 83.3 | |||||||||||||||
balance-sheet.row.total-debt | 220.28 | 62.4 | 16.3 | 7.8 | |||||||||||||||
balance-sheet.row.net-debt | -4396.1 | -1108.9 | -824.4 | -642.2 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 316.91 | 295.5 | 335.7 | 326.3 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 4.15 | 38.5 | 26.1 | 25.1 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0.5 | -1 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | -0.5 | 1 | |||||||||||||||
cash-flows.row.change-in-working-capital | 56.61 | 47.4 | -47.2 | 11.5 | |||||||||||||||
cash-flows.row.account-receivables | 66 | 0 | -30.9 | -34.6 | |||||||||||||||
cash-flows.row.inventory | -9.39 | -9.4 | 4.1 | -5.4 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | -20.9 | 52.5 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 56.8 | 0.5 | -1 | |||||||||||||||
cash-flows.row.other-non-cash-items | -35.67 | 0.7 | 45.7 | -2.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 342.01 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -178.88 | -209.2 | -188.7 | -122.2 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0.2 | 0 | |||||||||||||||
cash-flows.row.purchases-of-investments | -498.07 | -600.1 | -484.4 | -843.1 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 475.95 | 612.2 | 517.6 | 742.7 | |||||||||||||||
cash-flows.row.other-investing-activites | 9.92 | 5.1 | 37.1 | 10.2 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -191.08 | -191.9 | -118.2 | -212.3 | |||||||||||||||
cash-flows.row.debt-repayment | -27.75 | -20 | -5.8 | -5.8 | |||||||||||||||
cash-flows.row.common-stock-issued | 105.78 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.common-stock-repurchased | -85.78 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | -106.05 | -105.6 | -105.2 | -83.8 | |||||||||||||||
cash-flows.row.other-financing-activites | 56.95 | 77.2 | 0 | 0 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -40.9 | -23.4 | -111 | -89.6 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.01 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.net-change-in-cash | 218.6 | 166.8 | 131.1 | 58.7 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 3121.02 | 577.6 | 410.8 | 279.7 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 2902.42 | 410.8 | 279.7 | 221 | |||||||||||||||
cash-flows.row.operating-cash-flow | 342.01 | 382.1 | 360.3 | 360.6 | |||||||||||||||
cash-flows.row.capital-expenditure | -178.88 | -209.2 | -188.7 | -122.2 | |||||||||||||||
cash-flows.row.free-cash-flow | 163.12 | 172.9 | 171.5 | 238.4 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 880.01 | 848.2 | 896 | 807.7 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 40.98 | 40.2 | 41.3 | 34.4 | |||||||||||||||
income-statement-row.row.gross-profit | 839.02 | 808 | 854.7 | 773.3 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 118.35 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 12.92 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 334.49 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.62 | 1 | 16.1 | 28.5 | |||||||||||||||
income-statement-row.row.operating-expenses | 517.07 | 494.2 | 439.5 | 407.2 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 558.06 | 534.4 | 480.8 | 441.6 | |||||||||||||||
income-statement-row.row.interest-income | 29.94 | 31 | 24.8 | 22.6 | |||||||||||||||
income-statement-row.row.interest-expense | 1.36 | 1.3 | 0.4 | 0.4 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 334.49 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 14.39 | 1 | 2.5 | 0.1 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.62 | 1 | 16.1 | 28.5 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 14.39 | 1 | 2.5 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 1.36 | 1.3 | 0.4 | 0.4 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 4.05 | 38.5 | 75.9 | 27.2 | |||||||||||||||
income-statement-row.row.ebitda-caps | 360.93 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 345.1 | 345 | 396.2 | 392.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 359.49 | 346 | 398.7 | 393 | |||||||||||||||
income-statement-row.row.income-tax-expense | 56.64 | 50.4 | 63 | 66.7 | |||||||||||||||
income-statement-row.row.net-income | 316.91 | 310.2 | 348.8 | 338 |
Често задавани въпроси
Какво е Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) общи активи?
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) общите активи са 2562166715.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 389356160.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е 0.312.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е 0.312.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.360.
Какъв е общият приход на предприятието?
Общият приход е 0.392.
Каква е Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 310184878.000.
Какъв е общият дълг на фирмата?
Общият дълг е 62443059.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 494184515.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 1195259993.000.